Patients young and old deserve treatments that provide long-lasting immunity – even for the most difficult to treat diseases. With our proprietary #DendriticCell hyperactivation platform, we’re enabling a new era of rapid, patient-friendly and low-cost immunotherapies.

Co-founder and Board member Dr. @AMBellinger has spent his career building and growing biopharma companies including Lyndra® Therapeutics, CocoonBiotech and @BetterFitTech. He has spent the past 4 years as CSO and CMO of Verve Therapeutics, and has experience in research and clinical cardiology.

Our SAB features industry experts including Alan Ezekowitz, a partner at Third Rock Ventures. He is known for his work in phagocyte biology and innate immunity, as well as his roles as the Charles Wilder Professor of Pediatrics at @HarvardMed and Co-founder & CEO of Abide Therapeutics.

Our team had a fantastic time kayaking on the Charles, where we explored and bonded over our shared commitment to transforming the standard of care for infectious diseases and cancers. If you’d like to join our team, visit the Corner website: bit.ly/3rKaR7N

Corner’s broad antigen portfolio, ranging from complex to single neoantigens, allows us to generate personalized and off-the-shelf vaccines that can provide rapid, low-cost and durable immunity for all patients. Learn more about our science: bit.ly/3IMtgH4

The Corner team celebrated the beauty of autumn in New England with a fall paint night! While enjoying seasonal snacks and cocktails, we caught up with our coworkers and painted stunning landscapes together.

We had a wonderful time in San Diego at #SITC2023! Our Scientists Dania Zhivaki and @Emily_Gosselin, pictured here, shared the latest data on Corner’s proprietary immunotherapy platforms and connected with fellow researchers in immuno-oncology. Learn more: cornertx.com

Introducing Corner’s #CatalyticAdjuvant platform, published in @mBioJournal. Our platform moves beyond the use of mRNAs to produce antigens. Our mRNAs encode adjuvant-enzymes that induce strong CD8+ T & B cell responses. Read more: bit.ly/3sxqRL3

In addition to serving on our SAB, Arlene Sharpe is the George Fabyan Professor of Comparative Pathology at @HarvardMed. She's best known for her groundbreaking work on T cell co-stimulation and immune checkpoint inhibition, for which she’s been recognized with numerous awards.

As we begin the holiday season, our team got together for a pre-Thanksgiving potluck in the office! We value connection between our employees, and a delicious spread of food set the scene for a wonderful get-together. Learn more about working at Corner: bit.ly/3rKaR7N

Tomorrow is #Thanksgiving - we're incredibly thankful to be part of a team that shares a commitment to creating a new immunotherapy paradigm. Here are just a few reasons why our team members are thankful to be working on the cutting edge of biotech at Corner Therapeutics!

Corner's #CatalyticAdjuvant and #hDC platforms power our work to transform the field of immunotherapy. We're harnessing the power of dendritic cells to build a pipeline of novel therapies that could treat a broad range of cancers and infectious diseases. cornertx.com

Corner is excited to share our website’s newly revamped Science content! Visit our website to see new graphics and expanded content highlighting our work using Corner’s #hDC and #CatalyticAdjuvant platforms to treat cancer and infectious diseases: bit.ly/3kKqHvA

On Corner's SAB, Ruslan Medzhitov brings valuable insights from his years of research in immune regulation, inflammatory responses and mechanisms of host-microbial interactions. Dr. Medzhitov also serves as the Sterling Professor in the Department of Immunobiology at Yale School of Medicine.

Last week, the Corner team celebrated the holidays with a festive winter party! We had a wonderful time at Boston Winery, and want to wish everyone a safe and happy holiday season.

As we approach New Year’s Eve, Corner wishes everyone #HappyNewYear! We've made many strides in our work to develop a new class of muti-purpose immunotherapies in 2023, and we look forward to reaching important milestones with our incredible team in 2024. cornertx.com

Our Catalytic Adjuvant platform utilizes the only immunostimulatory protein that can be encoded by mRNA – while recently developed mRNA-LNP vaccines support the production of antigens, they display weak adjuvant activity. Learn more about our science: bit.ly/41MHobq

Our culture is based around essential cornerstones including curiosity – our team is motivated by a drive to pursue new ideas and push boundaries for the treatment of infectious diseases and cancers. Interested in becoming part of our team? Learn more: bit.ly/3rKaR7N

On our SAB, F. Stephen Hodi, MD, brings substantial expertise in immunotherapy for skin cancer. He is the Sharon Crowley Martin Chair in Melanoma at Dana-Farber, and was instrumental in the clinical development of ipilimumab and nivolumab for the treatment of melanoma.

It is Corner Therapeutics’ mission to bring a new class of immunotherapies to patients of all ages. We are committed to leveraging our #hDC and Catalytic Adjuvant platforms to develop novel therapies for a range of cancers and infectious diseases. bit.ly/3DY1mWi